COVID-19门诊患者急性静脉血栓栓塞的临床与遗传风险因素
该基于UK Biobank的人群队列研究纳入2020年3月1日至2021年9月3日经聚合酶链反应检测阳性的SARS-CoV-2感染者,并按倾向性评分与同期未感染者匹配,排除有VTE史、使用抗血栓药物或院内检测阳性者。结果显示,门诊COVID-19与30天内VTE风险显著升高相关(感染组与未感染组发生率分别为50.99/1000人年与2.37/1000人年;HR 21.42,95%CI 12.63-36.31),完全接种者风险大幅降低(HR 5.95,95%CI 1.82-19.5;交互作用P=0.02)。在COVID-19患者中,年龄较大、男性和肥胖与更高风险独立相关,遗传性易栓症与COVID-19后VTE风险相关(HR 2.05,95%CI 1.15-3.66)。作者认为这些发现可能强化疫苗接种需求,并为未接种门诊COVID-19患者的靶向VTE预防策略提供依据。
要点
- 门诊COVID-19与30天内VTE风险显著升高相关:感染组与未感染组发生率分别为50.99/1000人年与2.37/1000人年(HR 21.42,95%CI 12.63-36.31)。
- 完全接种者突破感染后VTE风险大幅降低:HR 5.95(95%CI 1.82-19.5),与未接种者的交互作用P=0.02。
- 在COVID-19患者中,年龄每增加10岁(aHR 1.87,95%CI 1.50-2.33)、男性(aHR 1.69,95%CI 1.30-2.19)、肥胖(aHR 1.83,95%CI 1.28-2.61)与更高的COVID-19后VTE风险独立相关。
- 遗传性易栓症与COVID-19后VTE风险相关:HR 2.05(95%CI 1.15-3.66)。
- 作者认为这些发现可能强化疫苗接种需求,有助于VTE风险分层,并呼吁对未接种门诊COVID-19患者采取靶向VTE预防策略。
适用人群与场景
- UK Biobank中2020年3月1日至2021年9月3日经聚合酶链反应检测阳性的SARS-CoV-2感染者(门诊COVID-19患者),按倾向性评分与同期COVID-19未感染者匹配。
- 排除有VTE史者、索引日期前1年内使用抗血栓药物者、院内检测阳性者。
研究设计与关键结果
- 研究类型:基于UK Biobank的人群队列研究;纳入18 818例COVID-19门诊患者(女性10 580例[56.2%];平均[SD]年龄64.3[8.0]岁)和93 179例匹配的未感染者(女性52 177例[56.0%];平均[SD]年龄64.3[7.9]岁)。
- 主要终点(感染后30天内复合VTE,包括深静脉血栓或肺栓塞):感染组与未感染组发生率分别为50.99/1000人年与2.37/1000人年,HR 21.42(95%CI 12.63-36.31)。
- 完全接种者中风险大幅降低:HR 5.95(95%CI 1.82-19.5),与疫苗接种状态的交互作用P=0.02。
- 在COVID-19患者中,年龄较大(每10年aHR 1.87,95%CI 1.50-2.33)、男性(aHR 1.69,95%CI 1.30-2.19)、肥胖(aHR 1.83,95%CI 1.28-2.61)与更高的COVID-19后VTE风险独立相关。
- 遗传性易栓症与COVID-19后VTE风险相关:HR 2.05(95%CI 1.15-3.66)。
证据类型、等级与局限
- 证据类型:基于UK Biobank的人群队列研究(倾向性评分匹配)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现可能强化疫苗接种需求,有助于VTE风险分层,并呼吁对未接种门诊COVID-19患者采取靶向VTE预防策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The risk of venous thromboembolism (VTE) in ambulatory COVID-19 is controversial. In addition, the association of vaccination with COVID-19-related VTE and relevant clinical and genetic risk factors remain to be elucidated.
OBJECTIVE: To quantify the association between ambulatory COVID-19 and short-term risk of VTE, study the potential protective role of vaccination, and investigate clinical and genetic risk factors for post-COVID-19 VTE.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of patients with COVID-19 from UK Biobank included participants with SARS-CoV-2 infection that was confirmed by a positive polymerase chain test reaction result between March 1, 2020, and September 3, 2021, who were then propensity score matched to COVID-19-naive people during the same period. Participants with a history of VTE who used antithrombotic drugs (1 year before index dates) or tested positive in hospital were excluded.
EXPOSURES: First infection with SARS-CoV-2, age, sex, ethnicity, socioeconomic status, obesity, vaccination status, and inherited thrombophilia.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite VTE, including deep vein thrombosis or pulmonary embolism, which occurred 30 days after the infection. Hazard ratios (HRs) with 95% CIs were calculated using cause-specific Cox models.
RESULTS: In 18 818 outpatients with COVID-19 (10 580 women [56.2%]; mean [SD] age, 64.3 [8.0] years) and 93 179 matched uninfected participants (52 177 women [56.0%]; mean [SD] age, 64.3 [7.9] years), the infection was associated with an increased risk of VTE in 30 days (incidence rate of 50.99 and 2.37 per 1000 person-years for infected and uninfected people, respectively; HR, 21.42; 95% CI, 12.63-36.31). However, risk was substantially attenuated among the fully vaccinated (HR, 5.95; 95% CI, 1.82-19.5; interaction P = .02). In patients with COVID-19, older age, male sex, and obesity were independently associated with higher risk, with adjusted HRs of 1.87 (95% CI, 1.50-2.33) per 10 years, 1.69 (95% CI, 1.30-2.19), and 1.83 (95% CI, 1.28-2.61), respectively. Further, inherited thrombophilia was associated with an HR of 2.05 (95% CI, 1.15-3.66) for post-COVID-19 VTE.
CONCLUSIONS AND RELEVANCE: In this population-based cohort study of patients with COVID-19, ambulatory COVID-19 was associated with a substantially increased risk of incident VTE, but this risk was greatly reduced in fully vaccinated people with breakthrough infection. Older age, male sex, and obesity were clinical risk factors for post-COVID-19 VTE; factor V Leiden thrombophilia was additionally associated with double the risk, comparable with the risk of 10-year aging. These findings may reinforce the need for vaccination, inform VTE risk stratification, and call for targeted VTE prophylaxis strategies for unvaccinated outpatients with COVID-19.
参考来源
- Xie J, Prats-Uribe A, Feng Q, et al. Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. JAMA Intern Med. 2022. PMID: 35980616. doi:10.1001/jamainternmed.2022.3858
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。